Pyoderma gangrenosum as an Early Revelator of Acute Leukemia
Universitair Ziekenhuis Ghent, Gand, Flemish, BelgiumDermatology (Impact Factor: 1.57). 02/2000; 200(2):176-8. DOI: 10.1159/000018360
Bullous pyoderma gangrenosum is an atypical, more superficial variety of the classical pyoderma and is often associated with myeloproliferative disorders. We present the case of a patient who presented initially with subcutaneous nodules and who developed bullous lesions afterwards. Histological evaluation showed the presence of neutrophilic infiltrates in both lesions. A few months after the diagnosis of bullous pyoderma gangrenosum, an underlying leukemia was revealed. Our case illustrates the importance of regular blood and bone marrow examinations in patients with atypical bullous pyoderma gangrenosum, resulting in a rapid diagnosis of the underlying disease.
- International Journal of Dermatology 03/2001; 40(2):144-7. DOI:10.1046/j.1365-4362.2001.01177-5.x · 1.31 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: A 33-year-old woman developed a bullous PG precursing a chronic myelomonocytic leukemia (CMML) complicated by life-threatening, disseminated, intravascular coagulation after administration of systemic corticosteroids in combination with immunosuppressant and antibiotic agents. Although the association between PG and leukemia, as well as the coincidence of disseminated intravascular coagulation (DIC) and leukemia, is well known, a premonitoring effect of PG in combination with DIC preceding the diagnosis of chronic myelomonocytic leukemia in the same patient has not been reported recently.The Journal of Dermatology 02/2003; 30(1):59-63. · 2.25 Impact Factor
- Archives of Dermatology 05/2004; 140(4):479-84. DOI:10.1001/archderm.140.4.479-g · 4.79 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.